ChromaDex, Inc.

234 articles about ChromaDex, Inc.

• ChromaDex Corporation Reports First Quarter 2021 Financial Results

  5/6/2021

  Tru Niagen® Revenue for the Three-Month Period Ended March 31, 2021 Totals $12.4 Million, up 12% Year-over-Year, with Total Company Revenue of $14.7 Million and Gross Margin of 62.9%.

• ChromaDex and Ro Partner for New Product Development

  5/4/2021

  ChromaDex Corp. announced that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company.

• ChromaDex to Present at Benzinga’s Global Small Cap Conference on May 13, 2021

  5/3/2021

  ChromaDex Corp. is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET.

• ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen®

  4/28/2021

  H&H Group expands Swisse® healthy aging product line into growing NAD+ space with Niagen® from ChromaDex

• ChromaDex Appoints Fadi Karam as Chief Marketing Officer

  4/19/2021

  Karam has spent his career driving consumer businesses across multiple geographies and cultures, including scaling direct-to-consumer operations across digital, social, and traditional marketing platforms, as well as launching and scaling product innovation.

• ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency

  3/31/2021

  ChromaDex External Research Program (CERP) and the Citrin Foundation to collaborate on series of studies exploring rare disease citrullinemia

• ChromaDex to Present at the Lytham Partners Spring 2021 Investor Conference

  3/24/2021

  ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Lytham Partners Spring 2021 Investor Conference.

• ChromaDex to Present at the Zooming with LD Virtual Investor Conference

  3/18/2021

  ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the Zooming with LD investor conference.

• ChromaDex Corporation Reports 2020 Financial Results

  3/10/2021

  Revenue for the Three-Month Period Ended December 31, 2020 Totals $15.4 Million, up 18% Year-over-Year, with Gross Margin of 61.0%, and Lower Operating Expenses.

• ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference

  3/9/2021

  ChromaDex to Present at Oppenheimer 31 st Annual Healthcare Conference

• ChromaDex Announces $25 Million Private Placement of Common Stock

  2/22/2021

  ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement was led by a new international investor and is expected to close on or about February 23, 2021, subject to the satisfaction of customary closing conditions.

• ChromaDex to Present at Benzinga’s Inaugural Small Cap Conference in December 2020

  12/2/2020

  ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the December 2020 Benzinga Small Cap Conference on Wednesday, December 9, 2020 at 11:15am ET (8:15am PT). This inaugural Small Cap Conference is a day dedicated to bridging the gap between Small Cap companies, investors and traders. The event will have multiple days of networking and education in a virtual setting. A webcast of the pr

• ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)

  11/17/2020

  Researchers to compare milk production among mothers of preterm infants while receiving ChromaDex’s ingredient nicotinamide riboside (Niagen®, or NR)

• ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership

  11/9/2020

  ChromaDex and Watsons Hong Kong launch new TRU NIAGEN® EX stick packs for on-the-go consumers in new delivery method

• ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020

  10/28/2020

  ChromaDex Corp. announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020.

• New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice

  10/19/2020

  New preclinical study finds boosting NAD+ with nicotinamide riboside alleviated telomere damage, providing protective effect to DNA strands

• Celltrient™ Cellular Energy Products Featuring Tru Niagen® Launch in US

  10/14/2020

  Nestlé Health Science launches Celltrient™ products to help fight key drivers of cell aging featuring ChromaDex’s flagship ingredient Tru Niagen®

• 

  Clinical Catch-Up: October 5-9

  10/12/2020

  It was a moderately busy week for clinical trial news. Here’s a look.

• New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function

  10/8/2020

  A study in Nature Immunology found that nicotinamide riboside (NR) improved the anti-cancer function of tumor infiltrating immune T-cells in mice

• ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%

  10/6/2020

  Phase 2 study finds addition of nutritional protocol to standard of care reduces recovery time to 6.6 days from 9.3 in mild-to-moderate COVID-19 patients LOS ANGELES--( BUSINESS WIRE )-- ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recovery in mild-to-moderate COVID-19” were published on the open access preprint publication server medRxiv.org . The Phase 2 study rep